Stay updated with breaking news from Optimizing Outcomes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.
A panel of medical experts open a discussion surrounding key treatment strategies in management of hepatocellular carcinoma (HCC).
Ghassan Abou-Alfa, MD, MBA, and Mohamed Salem, MD, provide insights regarding potential clinical pathway-driven challenges associated with HCC management.
Use of analog vs human insulin in patients receiving hemodialysis is associated with a lower risk for major adverse cardiovascular events, hospitalization, and death. Investigators compared analog and human insulin and major outcomes in patients with type 2 diabetes receiving hemodialysis.
Investigators compared analog and human insulin and major outcomes in patients with type 2 diabetes receiving hemodialysis.